A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers
Sponsor: Eli Lilly and Company
A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Jun 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- Loxo Oncology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .